Pharmacopeial-grade epinephrine bitartrate, supplied for tablet, capsule, granule, and injectable manufacture, is the 1:1 hydrogen L-(+)-tartrate addition salt of (–)-epinephrine. The compound is registered as CAS 51-42-3, has the molecular formula C₉H₁₃NO₃·C₄H₆O₆, and a molecular weight of 333.29 g/mol. The anhydrous salt contains 0.5497 g of epinephrine base per gram, a stoichiometric conversion factor that must be applied to batch calculations because compendial labeling is expressed in terms of epinephrine base. The API is a white to grayish-white crystalline powder with an assay acceptance interval of 97.0–102.0% on the dried basis. It is freely soluble in water, slightly soluble in ethanol, and practically insoluble in chlorinated solvents such as methylene chloride. This solubility profile makes the bitartrate salt appropriate for aqueous injectable compounding while still being processable in solid oral unit operations.

Commercial model numbers are supplier-specific; the specification is defined by the current USP monograph for Epinephrine Bitartrate and the corresponding Ph.Eur monograph for adrenaline tartrate. Product codes should therefore be mapped to monograph identity, salt stoichiometry, and route-specific attributes rather than being treated as separate chemical entities. Packaging is typically double low-density polyethylene liners inside an aluminum-foil laminate, closed under nitrogen to limit oxygen ingress. Storage requires a tight, light-resistant container at controlled room temperature; excursions above 25°C and relative humidity above 60% should be avoided. For solid oral processing, the API is often milled or sieved to a route-specific particle-size band. Laser diffraction method ISO 13320-1:2020 or USP 429 is used to monitor D₁₀, D₅₀, and D₉₀; a low-dose tablet blend may specify a D₉₀ from 50 µm to 150 µm, though the exact limit is formulation-dependent and should be established with product-specific stability data.

What Release Specifications and Compendial Methods Apply to the Bitartrate API?

Identity is confirmed by infrared absorption spectrophotometry using the compendial pellet technique and by a tartrate chemical identification. Assay is measured by high-performance liquid chromatography with ultraviolet detection, operated under USP 621 and qualified according to ICH Q2(R1). The column and mobile phase are selected so that norepinephrine and sulfonic acid oxidation products are separated from the epinephrine peak; failing resolution can produce an overestimate of potency. Loss on drying is determined by USP 731, residue on ignition by USP 281, and residual solvents by USP 467 with limits drawn from ICH Q3C. Elemental impurities are controlled through ICH Q3D and USP 232/233, with a risk assessment covering the manufacturing process, water quality, and packaging. For solid oral material, microbial enumeration follows USP 61 and USP 62; for injectable-oriented material, bacterial endotoxins are tested by USP 85 and the finished sterile product must meet USP 71.

Particle-size distribution is not a compendial identity criterion, but it is a critical formulation parameter. The powder may be characterized by bulk and tapped density per USP 616 and by compressibility index. Crystallinity is monitored by X-ray powder diffraction under USP 941 when the API is micronized because milling can introduce amorphous surface domains; amorphous domains increase surface free energy and accelerate oxidative darkening. A nitrogen overlay is maintained after milling, and headspace oxygen below 2% is used as an operational boundary. The API should not be exposed to strong oxidizing agents, alkaline conditions above pH 6, or transition-metal sources during packaging and sampling, because these conditions promote the adrenochrome degradation pathway.

Regulatory support generally includes a Type II US FDA drug master file for epinephrine bitartrate and, where applicable, a Certificate of Suitability to the European Pharmacopoeia monograph. Manufacturing should be performed under ICH Q7 GMP regardless of the intended route, with change control for milling, sieving, and packaging. Batch-to-batch variance is most commonly observed as subtle color change from white to grayish-pink; this appearance shift is a warning of oxidative stress rather than a routine acceptance criterion alone.

Solid Oral Dosage Form Processing and Stability Boundaries

Tablet and capsule development is constrained less by the bulk powder flow of the salt than by the low unit dose of epinephrine base. In many solid oral products, the epinephrine base content per unit is between 0.1 mg and 1.0 mg; at this level, content uniformity is the dominant process risk. A geometric preblend or ordered mixing step is used before final blending. Blend uniformity is assessed according to USP 905 using stratified sampling across the blender discharge port. Direct compression and roller compaction are preferred over aqueous wet granulation because the catechol ring can oxidize in the presence of moisture and heat. If wet granulation is unavoidable, the granulator inlet-air dew point should be maintained below 4°C and product temperature below 30°C during drying. On a rotary tablet press, precompression and main compression forces are set to achieve compact hardness without generating the localized frictional heat that darkens the tablet surface; a common trial range is 6–12 kN main compression for 4–8 kP hardness in standard concave tooling.

The freely soluble bitartrate salt rarely presents a dissolution-rate-limiting barrier in immediate-release tablet matrices, but hydrolysis and oxidation still influence formulation stability. Excipients containing reducing sugars or aldehydic degradation products should be excluded because they can react with the secondary amine. Alkaline fillers and buffers are incompatible because they raise the microenvironmental pH and accelerate oxidation to adrenochrome. Magnesium stearate may be used at low concentration; over-lubrication can still slow dissolution from compressed granules. Superdisintegrants that rely on high pH or ionic interaction should be selected only after compatibility studies under ICH Q1A(R2) conditions at 25°C/60% RH, 30°C/65% RH, and 40°C/75% RH.

Stability-indicating methods should be used to monitor the appearance of adrenochrome and norepinephrine. In solid oral development, forced degradation is performed under acid, base, peroxide, and light conditions per ICH Q1B; photostability of the unprotected salt is poor, so immediate protection from light in the formulation and package is required. Published data for this specific configuration is limited; therefore, formulators should generate product-specific stability data rather than extrapolating from epinephrine base or hydrochloride literature alone.

For oral granules, the same base equivalence and oxidative constraints apply. Dry blending or non-aqueous granulation is preferred. If aqueous granulation is used, the granulating fluid should be purged with nitrogen, and the binder system should be screened for metal-catalyzed degradation. For capsule filling, low fill weight requires flowable excipients; dosator and tamping-pin machines may require different granule densities. The capsule shell should be low-moisture and oxygen-barrier if the dosage is intended for long-term storage. A desiccant in the container is often used, but the exact desiccant quantity cannot be specified without product-specific moisture-sorption data.

For injectable manufacture, epinephrine bitartrate is dissolved in Water for Injection that has been purged with nitrogen and cooled to 15–20°C. The resulting solution is acidic; the finished parenteral monograph should be used to define the final pH, but values above 4.0 are generally avoided because the catechol oxidation rate increases with pH. The solution is sterile-filtered through a 0.22 µm sterilizing-grade membrane; filter compatibility must be confirmed because the catechol moiety can bind to some membrane polymers and reduce delivered potency. Holding vessels and filling lines are typically passivated 316L stainless steel to minimize iron and copper release, which catalyzes the adrenochrome pathway. Nitrogen blanketing is maintained in the receiving vessel and filling tank; residual headspace oxygen below 2% is a practical operating limit. The solution is protected from light during compounding, transfer, and filling.

Because terminal moist-heat sterilization can degrade the catechol ring and promote racemization, aseptic filtration followed by filling under Grade A conditions described in EU GMP Annex 1 is the usual manufacturing approach. The drug product is evaluated for sterility by USP 71, bacterial endotoxins by USP 85, and particulate matter by USP 788 or 787. For the API itself, the endotoxin limit is derived from the finished-product limit and maximum daily dose; a generic API endotoxin acceptance criterion cannot be assigned without that calculation. The API lot should also have a low bioburden before sterile filtration; filtration is not a substitute for controlling the prefilter bioburden.

Antioxidant selection is a finished-formulation issue, not an API property. Sodium metabisulfite is frequently used in injectable epinephrine formulations, but the bitartrate salt itself is supplied without antioxidant. Compounding records should account for the 0.5497 base-equivalence factor when converting the label claim from epinephrine base to salt mass. If the formulation is lyophilized, the collapse temperature and glass transition of the matrix must be determined because the acidic counterion and any buffer can depress the collapse temperature; published data for this specific lyophilized configuration is limited.

How the Bitartrate Salt Differs from Epinephrine Base and Hydrochloride in Formulation Use

Epinephrine base is practically insoluble in water and has a molecular weight of 183.20 g/mol; it is rarely used directly in aqueous injections. Epinephrine bitartrate adds L-(+)-tartaric acid as counterion, increasing molecular weight to 333.29 g/mol and reducing the base equivalence to 0.5497. Epinephrine hydrochloride has a molecular weight of 219.67 g/mol and a base equivalence of 0.8339. Both bitartrate and hydrochloride salts are freely soluble in water, but the bitartrate can provide a lower chloride load and different pH-buffer behavior. In solid oral forms, the bitartrate salt may form a slightly acidic microenvironment during dissolution; this is usually beneficial for epinephrine stability but can affect acid-labile excipients or enteric coatings. In injectable compounding, the bitartrate salt dissolves without generating hydrochloric acid on dilution, which can simplify compatibility with some container and excipient systems.

Stereochemical identity is essential; the API is the (–)-enantiomer, whereas racepinephrine is the racemic mixture and is not ionically identical to epinephrine bitartrate. The (–)-enantiomer is the pharmacologically active form at adrenoceptors. Enantiomeric purity should be controlled by optical rotation or chiral HPLC; the appropriate method depends on the current monograph and chiral separation capability. If a supplier offers epinephrine bitartrate without specifying enantiomeric identity, it should not be substituted for the compendial (–)-epinephrine salt in injectable or oral dosage forms.

Compatibility boundaries are explicit: avoid alkaline buffers, strong oxidizers, reducing sugars, primary and secondary amines as formulation adjuvants, and unprotected exposure to light. Do not combine the solid salt with metal powders or unpassivated steel surfaces during bulk handling. The API is not sterile unless the supplier is specifically authorized for sterile processing; otherwise, incoming material should be treated as low-bioburden and must pass downstream sterilization or aseptic filtration as required.